Castle Biosciences Inc. (CSTL) Financial Statements (2026 and earlier)

Company Profile

Business Address 1500 W. PARKWOOD AVE.
FRIENDSWOOD, TX 77546
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 8071 - Medical Laboratories (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments299,505287,542275,930275,151293,130279,785
Cash and cash equivalent116,72985,55682,23389,689119,70994,959
Short-term investments182,776201,986193,697185,462173,421184,826
Receivables43,38249,48252,31156,35351,21850,261
Inventory, net of allowances, customer advances and progress billings10,2548,6508,3666,8498,1356,572
Inventory10,2548,6508,3666,8498,1356,572
Other undisclosed current assets7,95611,89512,06111,0357,6718,154
Total current assets:361,097357,569348,668349,388360,154344,772
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization 251   222 
Operating lease, right-of-use asset14,79515,15115,50311,16411,58411,904
Long-term investments and receivables1,8782,0501,13212,1409181,106
Long-term investments    11,140  
Accounts and financing receivable, after allowance for credit loss1,8782,0501,1321,0009181,106
Intangible asset, including goodwill, after accumulated amortization, including:99,574101,849104,12577,904106,229110,569
Goodwill10,70010,70010,70010,70010,70010,700
Intangible asset, excluding goodwill, after accumulated amortization88,88291,15893,43367,21295,53799,877
Other undisclosed intangible asset, including goodwill, after accumulated amortization(8)(9)(8)(8)(8)(8)
Other noncurrent assets3,7691,2821,2411,2661,2281,831
Other undisclosed noncurrent assets97,19284,88574,06049,85350,90044,383
Total noncurrent assets:217,459205,217196,061152,327171,081169,793
TOTAL ASSETS:578,556562,786544,729501,715531,235514,565
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities65,93552,85946,37534,72847,44942,550
Accounts payable18,71112,21113,1818,5026,9016,810
Accrued liabilities47,22440,64833,19426,22640,54835,740
Debt519 1,9441,111379 
Other undisclosed current liabilities2,2232,4492,5711,4351,5641,745
Total current liabilities:68,67755,30850,89037,27449,39244,295
Noncurrent Liabilities
Long-term debt and lease obligation9,95410,3888,4609,24910,05610,304
Long-term debt, excluding current maturities9,64010,0498,0968,9219,74510,015
Finance lease, liability314339364328311289
Liabilities, other than long-term debt27,55228,54428,50314,88615,95218,911
Deferred income tax liabilities2,3353,2423,1268371,6074,220
Operating lease, liability25,21725,30225,37714,04914,34514,691
Other undisclosed noncurrent liabilities1,5001,5001,500   
Total noncurrent liabilities:39,00640,43238,46324,13526,00829,215
Total liabilities:107,68395,74089,35361,40975,40073,510
Equity
Equity, attributable to parent, including:470,873467,046455,376440,306455,835441,055
Additional paid in capital694,860688,729676,759666,120655,703650,270
Accumulated other comprehensive income (loss)26724039131230473
Accumulated deficit(224,284)(221,952)(221,451)(225,974)(200,126)(209,716)
Other undisclosed equity, attributable to parent302929292828
Total equity:470,873467,046455,376440,306455,835441,055
TOTAL LIABILITIES AND EQUITY:578,556562,786544,729501,715531,235514,565

Income Statement (P&L) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues87,01083,04386,18887,98886,31185,782
Cost of revenue(18,315)(18,704)(17,626)(16,383)(16,183)(15,609)
Gross profit:68,69564,33968,56271,60570,12870,173
Operating expenses(72,522)(71,143)(72,813)(99,533)(66,078)(65,094)
Operating income (loss):(3,827)(6,804)(4,251)(27,928)4,0505,079
Nonoperating income2,9922,8812,9443,0993,3723,404
Investment income, nonoperating2,8962,8332,9443,0993,3723,404
Other nonoperating income (expense)9648    
Interest and debt expense(24)(24)(21)(17)(92)(201)
Income (loss) from continuing operations before income taxes:(859)(3,947)(1,328)(24,846)7,3308,282
Income tax expense (benefit)382(115)4,6664231,705(6,013)
Net income (loss):(477)(4,062)3,338(24,423)9,0352,269
Other undisclosed net income (loss) attributable to parent(1,855)3,5611,185(1,425)555 
Net income (loss) available to common stockholders, diluted:(2,332)(501)4,523(25,848)9,5902,269

Comprehensive Income ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net income (loss):(477)(4,062)3,338(24,423)9,0352,269
Comprehensive income (loss):(477)(4,062)3,338(24,423)9,0352,269
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,828)3,7621,093(1,524)312645
Comprehensive income (loss), net of tax, attributable to parent:(2,305)(300)4,431(25,947)9,3472,914

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: